文献速递头颈外科

挽救性手术与免疫检查点抑制剂治疗复发性头颈部鳞状细胞癌的肿瘤学结局:一项单机构回顾性研究

Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study.
PubMed 文献 · Head Neck · 2022-08-05

本研究比较挽救性手术与免疫治疗在铂类化疗后复发性晚期头颈部鳞状细胞癌患者中的生存结局。挽救性手术后2年总生存率为68.6%,免疫治疗为24.6%。多因素回归显示挽救性手术与生存改善相关但未达统计学显著(HR 0.12,p=0.25)。作者认为经适当选择的可切除晚期复发性患者可能从挽救性手术中获益,但需更大规模前瞻性研究。

要点

  • 挽救性手术后2年总生存率为68.6%,免疫治疗为24.6%。
  • 多因素回归显示挽救性手术与生存改善相关但未达统计学显著(HR 0.12,p=0.25)。
  • 口腔/口咽癌亚组中挽救性手术较免疫治疗生存改善(HR 0.006,p=0.01),NLR>5与生存下降相关(HR 6.4,p=0.02)。

核心结论

  • 本回顾性单机构数据显示,经适当选择的可切除晚期复发性头颈部鳞状细胞癌患者接受挽救性手术可能获得生存改善,但需更大规模前瞻性研究。

研究设计与样本

  • 单机构回顾性研究,纳入铂类化疗后晚期(III期或IV期)复发性头颈部鳞状细胞癌患者。
  • 生存采用Kaplan-Meier法估计,多因素分析采用Cox回归。

主要发现

  • 挽救性手术后2年总生存率为68.6%,免疫治疗为24.6%。
  • 多因素回归显示挽救性手术与生存改善相关但未达统计学显著(HR 0.12,p=0.25)。
  • 口腔/口咽癌亚组中,挽救性手术较免疫治疗生存改善(HR 0.006,p=0.01),中性粒细胞与淋巴细胞比值(NLR)>5与生存下降相关(HR 6.4,p=0.02)。

关键数值与推荐

  • 挽救性手术后2年总生存率68.6%,免疫治疗24.6%。
  • 挽救性手术 vs 免疫治疗:HR 0.12(p=0.25),未达统计学显著。
  • 口腔/口咽癌亚组:挽救性手术 vs 免疫治疗 HR 0.006(p=0.01);NLR>5 HR 6.4(p=0.02)。

临床怎么用

  • 作者认为,经适当选择的可切除晚期复发性头颈部鳞状细胞癌患者接受挽救性手术可能获得生存改善。
  • 作者指出需更大规模前瞻性研究验证。

局限性

  • 原文为单机构回顾性研究。
  • 多因素回归中挽救性手术与生存改善的关联未达统计学显著(HR 0.12,p=0.25)。
  • 作者指出需更大规模前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival outcomes in recurrent head and neck squamous cell carcinoma (HNSCC) are poor. This study aimed to compare survival outcomes between salvage surgery and immunotherapy in patients with recurrent advanced HNSCC. METHODS: Patients with advanced stage (stage III or IV) recurrent HNSCC following treatment with platinum-based chemotherapy were included. Survival was estimated using the Kaplan-Meier method, and Cox regression was used for multivariate logistic regression. RESULTS: Two-year overall survival after salvage surgery was 68.6% and after immunotherapy patients was 24.6%. Multivariate logistic regression showed that salvage surgery was associated with improved survival without statistical significance (hazard ratio [HR] 0.12, p = 0.25). Subgroup analysis of patients with oral cavity/oropharyngeal cancer noted improved survival with salvage surgery over immunotherapy (HR 0.006, p = 0.01) and decreased survival with neutrophil-to-lymphocyte ratio (NLR) > 5 (HR 6.4, p = 0.02). CONCLUSION: Our retrospective single-institutional data suggest that resectable advanced stage recurrent HNSCC may have improved survival with salvage surgery in appropriately selected patients, but larger prospective studies are required.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Konuthula N, Do OA, Gobillot T, et al. Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study. Head Neck. 2022. PMID: 35930296. doi:10.1002/hed.27162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。